# A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer

> **NCT02657551** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 8 (actual)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT02657551
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-01
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02657551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02657551, "A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT02657551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*